HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus.

AbstractBACKGROUND:
Oral mechanistic target of rapamycin inhibitors have been shown to reduce visceral tumor volume in patients with tuberous sclerosis complex (TSC).
OBJECTIVE:
We sought to evaluate the cutaneous response to oral sirolimus in patients with TSC and an indication for systemic treatment, including long-term effects.
METHODS:
A retrospective analysis of 14 adult patients with TSC prescribed sirolimus to treat lymphangioleiomyomatosis was performed. Serial photographs of angiofibromas, shagreen patches, and ungual fibromas taken before, during, and after the treatment period were blinded, then assessed using the Physician Global Assessment of Clinical Condition (PGA). Microscopic and molecular studies were performed on skin tumors harvested before and during treatment.
RESULTS:
Sirolimus significantly improved angiofibromas (median treatment duration 12 months; median PGA score 4.5 [range 1.5-5]; Wilcoxon signed rank test, P = .018) and shagreen patches (median treatment duration 10 months; median PGA score 4.5 [range 3.5-5]; Wilcoxon signed rank test, P = .039), whereas ungual fibromas improved in some patients (median treatment duration 6.5 months; median PGA score 4.66 [range 2.75-5]; Wilcoxon signed rank test, P = .109). Clinical, immunohistochemical, or molecular evidence of resistance was not observed (range 5-64 months of treatment).
LIMITATIONS:
This was a retrospective analysis limited to adult women with lymphangioleiomyomatosis.
CONCLUSION:
Oral sirolimus is an effective long-term therapy for TSC skin tumors, particularly angiofibromas, in patients for whom systemic treatment is indicated.
AuthorsNeera Nathan, Ji-an Wang, Shaowei Li, Edward W Cowen, Mary Haughey, Joel Moss, Thomas N Darling
JournalJournal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 73 Issue 5 Pg. 802-8 (Nov 2015) ISSN: 1097-6787 [Electronic] United States
PMID26365597 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightPublished by Elsevier Inc.
Chemical References
  • Antibiotics, Antineoplastic
  • Ribosomal Protein S6
  • Sirolimus
Topics
  • Acne Vulgaris (chemically induced)
  • Administration, Oral
  • Adult
  • Antibiotics, Antineoplastic (administration & dosage, adverse effects)
  • Drug Administration Schedule
  • Female
  • Humans
  • Middle Aged
  • Oral Ulcer (chemically induced)
  • Retrospective Studies
  • Ribosomal Protein S6 (analysis)
  • Sirolimus (administration & dosage, adverse effects)
  • Skin Neoplasms (drug therapy)
  • Treatment Outcome
  • Tuberous Sclerosis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: